Datopotamab deruxtecan, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CAPECITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion.
Phase 3 small_molecule active
Quick answer
Datopotamab deruxtecan, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CAPECITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion. for Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy. is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active